| Literature DB >> 33134988 |
Cody S Lee1, Manoj Reddy2, Bryan Scott2, Daniel Curtis2, Farid Amirouche3, Aravind Athiviraham2.
Abstract
PURPOSE: To investigate the potential for a suture tape-reinforcement technique to prevent elongation with repetitive use of a human dermal (HD) allograft traditionally used for superior capsule reconstruction in a biomechanical model.Entities:
Year: 2020 PMID: 33134988 PMCID: PMC7588633 DOI: 10.1016/j.asmr.2020.05.015
Source DB: PubMed Journal: Arthrosc Sports Med Rehabil ISSN: 2666-061X
Fig 1Schematic representation of suture-reinforcement. (A, anterior; P, posterior; M, medial; L, lateral); black color represents graft borders, blue represents suture tape reinforcement, maroon represents medial row anchors on glenoid, and orange and green represent the suture from the 2 anchors used for the linked, double row repair. X is placed at medial and lateral edges of the HD allograft represents where the 2 suture tapes were tied. (HD, human dermal.)
Fig 2Suture-reinforced HD allograft before testing. The graft is shown before tying of sutures at medial and lateral edges to better illustrate the use of the 2 sutures used. (HD, human dermal.)
Fig 3Biomechanical testing setup shown using a reinforced HD allograft; left shows side-view of testing setup; right shows front-view of testing setup. (HD, human dermal.)
Percent Change in Graft Dimensions Following Testing∗
| Native | 95% CI | Suture-Reinforced | 95% CI | ||
|---|---|---|---|---|---|
| Medial width | –21.05 ± 2.94% | –18.17% to – 23.93% | –5.80 ± 4.17% | –1.71% to – 9.89% | .001 |
| Lateral width | –19.29 ± 1.64% | –17.68% to –20.90% | –5.45 ± 3.70% | –1.82% to –9.08% | <.001 |
| Anterior length | +14.50 ± 3.13% | +11.43% to +17.57% | +6.36 ± 3.50% | +2.93% to +9.79% | .013 |
| Posterior length | +13.68 ± 2.64% | +11.09% to +16.27% | +6.00 ± 1.53% | +4.50% to +7.50% | .002 |
| Medial thickness | –17.93 ± 3.80% | –14.21% to – 21.65% | –4.38 ± 5.12% | 0.00% to –9.40% | .005 |
| Central thickness | –16.11 ± 3.19% | –12.98% to – 19.24% | –7.03 ± 5.28% | –1.86% to –12.20% | .026 |
| Lateral thickness | –20.80 ± 2.54% | –18.31% to –23.29% | –4.55 ± 4.55% | –0.09% to –9.01% | <.001 |
CI, confidence interval.
Values demonstrate average ± standard deviation; (+) values indicate material lengthening and (–) values indicate material shrinkage.
Fig 4Percent change in graft dimensions following testing.
Linear stiffness (N/mm) Values Obtained for Native Versus Augmented HD Allografts∗
| Native | Suture-Reinforced | ||
|---|---|---|---|
| Cycle 1 | 17.69 ± 1.91 | 21.18 ± 1.03 | .024 |
| Cycle 15 | 24.93 ± 2.79 | 29.90 ± 1.45 | .034 |
| Cycle 30 | 25.72 ± 3.01 | 32.13 ± 1.98 | .016 |
HD, human dermal.
Values demonstrate average ± standard deviation (N/mm).